Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure

Journal of Applied Genetics

Volumn 54, Issue 4, 2013, Pages 447-453

  Szmit, Sebastian ^a,b   Jank, Michał ^c   Maciejewski, Henryk ^d   Balsam, Paweł ^a   Łój, Magdalena ^c   Filipiak, Krzysztof J ^a   Motyl, Tomasz ^c   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Postgraduate Medical Education Center   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^d WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Acute heart failure; Gene expression profile; HER2 receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INOTROPIC AGENT; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; TROPONIN;

ACUTE HEART FAILURE; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HEART EJECTION FRACTION; HUMAN; HYBRIDIZATION; LUNG EDEMA; MALE; NEW YORK HEART ASSOCIATION CLASS; RNA ISOLATION; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; FEMALE; GENE EXPRESSION; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEUREGULIN-1; PROGNOSIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TROPONIN;

EID: 84886739006     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13353-013-0164-y     Document Type: Article

References (32)

1. Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11(Suppl 1): 4-12.
2. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25): 3910-3916.
3. Cheng H, Force T (2010) Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106: 21-34.
4. Chien KR (2006) Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 354(8): 789-790.
5. Criscitiello C, Curigliano G (2013) HER2 signaling pathway and trastuzumab cardiotoxicity. Future Oncol 9(2): 179-181.
6. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465.
7. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23(Suppl 7): vii155-vii166.
8. Ewer MS, Vooletich MT, Valero V, Higano CS, Benjamin RS (2002) Trastuzumab (Herceptin) cardiotoxicity: clinical course and cardiac biopsy correlations. Proc Am Soc Clin Oncol 21: 123a (abstr. 489).
9. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23(31): 7820-7826.
10. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20(1): 93-99.
11. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, Amor R, Liu X, Li XY, Zhou MD, Graham RM, Macdonald PS (2011) Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 13(1): 83-92.
12. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB, Cappola TP (2009) Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 120(4): 310-317.
13. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J (2012) Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 23(3): 791-800.
14. Liu FF, Stone JR, Schuldt AJ, Okoshi K, Okoshi MP, Nakayama M, Ho KK, Manning WJ, Marchionni MA, Lorell BH, Morgan JP, Yan X (2005) Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 289: H660-H666.
15. Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62(11): 3151-3158.
16. Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59: 1-12.
17. Nielsen DL, Kümler I, Palshof JA, Andersson M (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22(1): 1-12.
18. Opolski G, Krzakowski M, Szmit S, Banach J, Chudzik M, Cygankiewicz I, Drożdż J, Filipiak KJ, Grabowski M, Kaczmarek K, Kochman J, Lewek J, Maciejewski M, Miśkiewicz Z, Niwińska A, Pieńkowski T, Piestrzeniewicz K, Sinkiewicz W, Wranicz JK, Zawilska K; Task Force of National Consultants in Cardiology and Clinical Oncology (2011) Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer. The Task Force of National Consultants in Cardiology and Clinical Oncology for the elaboration of recommendations of cardiologic proceeding with patients with breast cancer. Kardiol Pol 69(5): 520-530.
19. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hübner N, Chien KR, Birchmeier C, Garratt AN (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99: 8880-8885.
20. Perez EA (2008) Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 8(Suppl 3): S114-S120.
21. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008a) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83(6): 679-686.
22. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ (2008b) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8): 1231-1238.
23. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28(21): 3422-3428.
24. Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, Paton V, Holmgren E, Mahaffey KW (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28(21): 3416-3421.
25. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105(13): 1551-1554.
26. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5): 1215-1221.
27. Speyer J (2002) Cardiac dysfunction in the trastuzumab clinical experience. J Clin Oncol 20: 1156-1157.
28. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25(25): 3859-3865.
29. Szmit S, Kurzyna M, Glówczynska R, Grabowski M, Kober J, Czerniawska J, Filipiak KJ, Opolski G, Szczylik C (2010) Manageability of acute severe heart failure complicated with left ventricular thrombosis during therapy for breast cancer. Int Heart J 51(2): 141-145.
30. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31): 7811-7819.
31. Valero V, Gill E, Paton V, Chang H-Y, Buzdar AU, Park G, Hortobagyi G, Ewer M (2004) Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol. 23: 20 (abstr. 572).
32. Yan X, Morgan JP (2011) Neuregulin1 as novel therapy for heart failure. Curr Pharm Des 17(18): 1808-1817.